No­var­tis takes a gam­ble on Voy­ager's new AAV tech, inks $1.7B gene ther­a­py dis­cov­ery pact

What­ev­er Voy­ager is com­ing up with on its new gene ther­a­py plat­form, No­var­tis wants a piece of it.

Voy­ager, which piv­ot­ed back in­to dis­cov­ery last year fol­low­ing a streak of set­backs on its clin­i­cal ef­forts, is set to re­ceive $54 mil­lion up­front in a deal li­cens­ing its new class of AAV cap­sids to No­var­tis for ap­pli­ca­tion on three undis­closed CNS tar­gets — plus op­tions to ex­pand the pact to in­clude two more tar­gets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER